Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab, and olaparib in newly diagnosed advanced ovarian cancer
jRCT2080224151Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of durvalumab, olaparib, bevacizumab, carboplatin and paclitaxel in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by AstraZeneca. Started Nov 2018; status: completed.
02
Drugs
durvalumabolaparibbevacizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2080224151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224151.